Outcomes of pars plana placement of Aurolab Aqueous Drainage Implant in neovascular glaucoma.

PurposeTo study the outcomes of pars plana placement of Aurolab Aqueous Drainage Implant (AADI) in neovascular glaucoma (NVG).Study design: retrospective study.MethodsTwenty-eight eyes were evaluated on postoperative days 1, 2 weeks, 6 weeks, 6 and 12 months postoperatively. Baseline and follow-up visits were compared to determine significant differences in intraocular pressure (IOP), the number of antiglaucoma medications (AGM), and best-corrected visual acuity (BCVA), surgical success, complications and interventions.ResultsMean IOP decreased from preoperative 46.2 ± 8.6 mmHg to 32.07 ± 13.0 mmHg,23.08 ± 12.8 mmHg,21.0 ± 14.4 mmHg, and 22.6 ± 19.5 mmHg at two weeks, six weeks, six months, and one year, respectively. AGM decreased from 3 preoperatively to 2.42, 1.37, 1.37,1.55, and 1.65 at two weeks, six weeks, six and 12 months, respectively. There was no significant difference in BCVA at any time point compared to baseline. Complete success was achieved in 50% and 37.5% of cases (using criteria 1: IOP ≤ 18 mmHg or 30% reduction from baseline without AGM, and criteria 2: IOP ≤ 15 mmHg or 40% reduction) after 12 months. Qualified success was observed in 83.3% and 72.2% of patients (using criteria 1: IOP ≤ 18 mmHg or a 30% reduction from baseline with a single AGM, and criteria 2: IOP ≤ 15 mmHg or a 40% reduction) after 12 months.ConclusionThis study demonstrates that pars plana placement of AADI in NVG achieves good surgical success regarding IOP control and visual acuity.